Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 132

Similar articles for PubMed (Select 22422492)

1.

Patient-reported outcomes in polymyalgia rheumatica.

Matteson EL, Maradit-Kremers H, Cimmino MA, Schmidt WA, Schirmer M, Salvarani C, Bachta A, Dejaco C, Duftner C, Slott Jensen H, Poór G, Kaposi NP, Mandl P, Balint PV, Schmidt Z, Iagnocco A, Cantini F, Nannini C, Macchioni P, Pipitone N, Del Amo M, Espígol-Frigolé G, Cid MC, Martínez-Taboada VM, Nordborg E, Direskeneli H, Aydin SZ, Ahmed K, Hazelman B, Pease C, Wakefield RJ, Luqmani R, Abril A, Marcus R, Gonter NJ, Maz M, Crowson CS, Dasgupta B.

J Rheumatol. 2012 Apr;39(4):795-803. doi: 10.3899/jrheum.110977. Epub 2012 Mar 15.

PMID:
22422492
2.

Plasma fibrinogen along with patient-reported outcome measures enhances management of polymyalgia rheumatica: a prospective study.

McCarthy EM, MacMullan PA, Al-Mudhaffer S, Madigan A, Donnelly S, McCarthy CJ, Molloy ES, Kenny D, McCarthy GM.

J Rheumatol. 2014 May;41(5):931-7. doi: 10.3899/jrheum.131055. Epub 2014 Apr 1.

PMID:
24692520
3.

Ultrasonographic monitoring of response to therapy in polymyalgia rheumatica.

Jiménez-Palop M, Naredo E, Humbrado L, Medina J, Uson J, Francisco F, García-Yebenes MJ, Garrido J.

Ann Rheum Dis. 2010 May;69(5):879-82. doi: 10.1136/ard.2009.113555. Epub 2009 Sep 22.

PMID:
19773289
4.

Corticosteroid injections in polymyalgia rheumatica: a double-blind, prospective, randomized, placebo controlled study.

Salvarani C, Cantini F, Olivieri I, Barozzi L, Macchioni L, Boiardi L, Niccoli L, Padula A, Pulsatelli L, Meliconi R.

J Rheumatol. 2000 Jun;27(6):1470-6.

PMID:
10852273
5.

EULAR response criteria for polymyalgia rheumatica: results of an initiative of the European Collaborating Polymyalgia Rheumatica Group (subcommittee of ESCISIT).

Leeb BF, Bird HA, Nesher G, Andel I, Hueber W, Logar D, Montecucco CM, Rovensky J, Sautner J, Sonnenblick M.

Ann Rheum Dis. 2003 Dec;62(12):1189-94.

6.
7.

Polymyalgia rheumatica and giant cell arteritis in older patients: diagnosis and pharmacological management.

Schmidt J, Warrington KJ.

Drugs Aging. 2011 Aug 1;28(8):651-66. doi: 10.2165/11592500-000000000-00000. Review.

PMID:
21812500
8.

Adverse outcomes of antiinflammatory therapy among patients with polymyalgia rheumatica.

Gabriel SE, Sunku J, Salvarani C, O'Fallon WM, Hunder GG.

Arthritis Rheum. 1997 Oct;40(10):1873-8.

PMID:
9336424
9.

Clinical outcomes, quality of life, and diagnostic uncertainty in the first year of polymyalgia rheumatica.

Hutchings A, Hollywood J, Lamping DL, Pease CT, Chakravarty K, Silverman B, Choy EH, Scott DG, Hazleman BL, Bourke B, Gendi N, Dasgupta B.

Arthritis Rheum. 2007 Jun 15;57(5):803-9.

10.

Diagnosis, differential diagnosis and treatment of polymyalgia rheumatica.

Nothnagl T, Leeb BF.

Drugs Aging. 2006;23(5):391-402. Review.

PMID:
16823992
11.

Contribution of the polymyalgia rheumatica activity score to glucocorticoid dosage adjustment in everyday practice.

Cleuziou C, Binard A, De Bandt M, Berthelot JM, Saraux A.

J Rheumatol. 2012 Feb;39(2):310-3. doi: 10.3899/jrheum.110866. Epub 2011 Dec 15.

PMID:
22174199
12.

Corticosteroid requirements in polymyalgia rheumatica.

Weyand CM, Fulbright JW, Evans JM, Hunder GG, Goronzy JJ.

Arch Intern Med. 1999 Mar 22;159(6):577-84.

PMID:
10090114
13.

Adrenal gland hypofunction in active polymyalgia rheumatica. effect of glucocorticoid treatment on adrenal hormones and interleukin 6.

Cutolo M, Straub RH, Foppiani L, Prete C, Pulsatelli L, Sulli A, Boiardi L, Macchioni P, Giusti M, Pizzorni C, Seriolo B, Salvarani C.

J Rheumatol. 2002 Apr;29(4):748-56.

PMID:
11950017
14.

Giant cell arteritis and polymyalgia rheumatica: pathophysiology and management.

Gonzalez-Gay MA, Garcia-Porrua C, Miranda-Filloy JA, Martin J.

Drugs Aging. 2006;23(8):627-49. Review.

PMID:
16964987
15.

Treatment of polymyalgia rheumatica: a systematic review.

Hernández-Rodríguez J, Cid MC, López-Soto A, Espigol-Frigolé G, Bosch X.

Arch Intern Med. 2009 Nov 9;169(20):1839-50. doi: 10.1001/archinternmed.2009.352. Review.

PMID:
19901135
16.

Deflazacort versus methylprednisolone in polymyalgia rheumatica: clinical equivalence and relative antiinflammatory potency of different treatment regimens.

Di Munno O, Imbimbo B, Mazzantini M, Milani S, Occhipinti G, Pasero G.

J Rheumatol. 1995 Aug;22(8):1492-8.

PMID:
7473472
17.

The correct prednisone starting dose in polymyalgia rheumatica is related to body weight but not to disease severity.

Cimmino MA, Parodi M, Montecucco C, Caporali R.

BMC Musculoskelet Disord. 2011 May 14;12(1):94. doi: 10.1186/1471-2474-12-94.

18.

[Rheumatic polymyalgia].

Calvo Romero JM, Ramos Salado JL, Pérez Miranda M.

An Med Interna. 2000 Jan;17(1):42-6. Spanish.

PMID:
10730406
19.

Treatment of refractory polymyalgia rheumatica with etanercept: an open pilot study.

Catanoso MG, Macchioni P, Boiardi L, Pipitone N, Salvarani C.

Arthritis Rheum. 2007 Dec 15;57(8):1514-9.

20.

Polymyalgia Rheumatica (PMR) Special Interest Group at OMERACT 11: outcomes of importance for patients with PMR.

Mackie SL, Arat S, da Silva J, Duarte C, Halliday S, Hughes R, Morris M, Pease CT, Sherman JW, Simon LS, Walsh M, Westhovens R, Zakout S, Kirwan JR.

J Rheumatol. 2014 Apr;41(4):819-23. doi: 10.3899/jrheum.131254. Epub 2014 Feb 1. Review.

PMID:
24488422
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk